A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice
NCT03457012 · Completed
Last updated 2026-05-28This study is testing how the medication semaglutide affects blood sugar levels in adults with type 2 diabetes as part of regular medical care in Canada.
What this study is testing ClinicalTrials.gov NCT03457012 ↗
Description as written by the study sponsor.
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by the study doctor. The study will last for about 6 to 8 months. Participants will be asked to complete some questionnaires about the health and the diabetes treatment. Participants will complete these during the normally scheduled visits with the study doctor.
Treatments tested
- Semaglutide Drug
Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
| Main thing measured | Change in Glycated Haemoglobin A1c (HbA1c) |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Conditions studied | Diabetes Mellitus, Type 2 |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03457012 ↗